InvestorsHub Logo
Followers 14
Posts 649
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Wednesday, 03/22/2017 6:57:15 PM

Wednesday, March 22, 2017 6:57:15 PM

Post# of 462051
avxl also has to be extremely cautious (as someone else mentioned here today) that none of the various indications run into roadblocks like what happened at Mannkind .... there is much less risk of this happening if they piece out the indications to specialists and back things up with strong contract law on such things as performance..... and for those that are adamant that they want it all .... better look at what Gilead paid for hep C..... if they pay up big they would then have to commercialize the indications for financial reasons....
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News